Bank of America Corp DE Sells 220,442 Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL)

Bank of America Corp DE trimmed its position in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 82.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,598 shares of the company's stock after selling 220,442 shares during the quarter. Bank of America Corp DE's holdings in Autolus Therapeutics were worth $110,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of AUTL. Jane Street Group LLC bought a new stake in Autolus Therapeutics during the 4th quarter worth approximately $26,000. Barclays PLC increased its stake in shares of Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after buying an additional 10,866 shares in the last quarter. Daiwa Securities Group Inc. increased its stake in shares of Autolus Therapeutics by 55.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock valued at $56,000 after buying an additional 8,479 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of Autolus Therapeutics by 29.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock valued at $62,000 after buying an additional 6,081 shares during the last quarter. Finally, Bayesian Capital Management LP lifted its position in Autolus Therapeutics by 177.8% during the 4th quarter. Bayesian Capital Management LP now owns 65,000 shares of the company's stock worth $153,000 after buying an additional 41,600 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Truist Financial lowered their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Wells Fargo & Company dropped their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, June 12th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Trading Down 0.2%

Shares of NASDAQ:AUTL traded down $0.01 during trading on Friday, hitting $2.06. 660,034 shares of the company's stock were exchanged, compared to its average volume of 1,567,638. The firm has a 50-day moving average price of $1.62 and a two-hundred day moving average price of $1.92. Autolus Therapeutics PLC Sponsored ADR has a 1-year low of $1.11 and a 1-year high of $5.00. The firm has a market cap of $546.92 million, a P/E ratio of -2.34 and a beta of 1.76.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The business had revenue of $8.98 million for the quarter, compared to analysts' expectations of $1.59 million. As a group, research analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.